Mayo Clinic- Jacksonville
Kidney Cancer Program
Address
4500 San Pablo Rd SJacksonville, FL, 32224
Key Contacts
Department Chair:
Vamsidhar Velcheti
Vamsidhar Velcheti
Medical Oncology Lead:
Arnab Basu M.B.B.S.
Arnab Basu M.B.B.S.
Urologic Surgery Lead:
Dr. David Thiel
Dr. David Thiel
Volume
Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.
Kidney Cancer Surgery Volume
HighClear Cell Kidney Cancer Diagnosis Volume
HighNon–Clear Cell Kidney Cancer Diagnosis Volume
MediumClinical Trial Participation Volume
HighRadiation & Ablation Procedure Volume
HighAbout these ratings
Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.
Types of Services Offered
Clinical Trials 
End of Life Services 
Genetic Counseling 
Infusion Center 
Integrative Oncology 
Molecular Testing 
Multidisciplinary Clinic 
Oncology Urgent Care Clinic 
Palliative & Supportive Care 
Patient Case Discussions / Tumor Boards 
Precision Medicine 
Survivorship Clinics 
Interventional Radiology 
Medical Oncology 
Pain Management 
Palliative Care 
Pathology 
Radiation Oncology 
Radiology 
Urologic Surgery Kidney Cancer Types & Expertise
Chromophobe RCC Clear Cell RCC Collecting Duct RCC Papillary RCC Renal Medullary Carcinoma Translocation RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pediatric (diagnosed under age 18) Pregnancy Solitary Kidney Young Adult (age 18-50)
Special Programs, Recognitions & Outcomes
American College of Surgeons Accredited Cancer Program Government-Funded Research Member of Kidney Cancer Consortium NCI Designated Cancer Center
Consortium Member
SWOG/ALLIANCE
Research Programs
Clinical 
Multi-Institutional Collaboration 
Population-Based 
Research Lab 
Translational Multi-Institutional Collaborations
Mayo Clinic Comprehensive Cancer Center (Arizona, Florida, and Minnesota campuses)
National Comprehensive Cancer Network (NCCN)
National Cancer Institute (NCI) cooperative group and multicenter clinical trial networks
International academic and industry research collaborations
Mayo Clinic multidisciplinary kidney cancer research collaboration
Patient Resources & Support Services
Fertility Preservation Counseling 
Financial Navigators 
Interpreter Services 
Lodging / Long-Term Housing 
Lymphedema Therapy 
Nurse Navigators 
Nutrition Services / Dietician 
Occupational Therapy 
On-site Dispensing / Pharmacy 
Parking Assistance (valet or concierge) 
Pastoral / Spiritual Care 
Patient Navigators 
Peer Support Options 
Physical Therapy 
Psychiatrists / Psychologists 
Remote Monitoring Tools 
Social Workers / Counselors 
Transportation Service 
Wellness Center Insurance Carriers
Accepted
- Aetna
- Blue Cross Blue Shield
- Cigna
- Humana
- UnitedHealthcare (participating plans)
- Multiplan / PHCS
- First Health Network
- TRICARE
- Medicare
- Medicare Supplement (Medigap)
- Medicaid
Not Accepted
- Medicare Advantage Plans
Open Clinical Trials
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.<br />
<br />
In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.<br />
<br />
To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.<br />
<br />
Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.